Amgen Inc.

🇺🇸NASDAQ Global Select

Articles

57
Show Summary
Show Bulletpoints
Detailed View
Bullish +65

Fort Washington Investment Advisors Inc. OH Has $32.40 Million Position ...

📈 Fort Washington added 4,559 shares, holding 92,090 total valued at $32.4M.

📊 Dogwood Wealth and Anfield Capital increased stakes by 275% and 1,000%.

📉 SVP Nancy Grygiel sold 1,237 shares, reducing her position by 15%.

💰 Amgen Q1 EPS hit $5.15 vs $4.77 estimate; revenue grew 5.8% YoY.

🏥 Company maintains 137.41% ROE, 20.96% net margin, and 76.50% institutional ownership.

📈 Fort Washington Investment Advisors Inc. boosted its Amgen stake by 5.2% in Q1, adding 4,559 shares to a total holding of 92,090 shares.

💰 The position held by Fort Washington is valued at $32.4 million as of the most recent SEC disclosure.

📊 Dogwood Wealth Management increased its stake by 275% in Q4, while Anfield Capital Management raised holdings by 1,000%.

📉 SVP Nancy A. Grygiel sold 1,237 shares for $400,454 on May 4th, reducing her personal position by 15%.

💵 Amgen reported Q1 EPS of $5.15, surpassing the consensus estimate of $4.77 by $0.38.

📈 Revenue reached $8.62 billion in the quarter, exceeding the $8.58 billion consensus and growing 5.8% year-over-year.

🏥 The company maintains a high return on equity of 137.41% and a net margin of 20.96%.

📅 Amgen provided FY 2026 guidance for EPS between $21.70 and $23.10.

🎯 Analysts currently anticipate FY 2026 earnings per share to average $22.38.

🏢 Institutional investors and hedge funds collectively own 76.50% of the company's outstanding stock.

Bullish Signals
  • Amgen beat EPS ($5.15) and revenue ($8.62B) estimates.
  • Strong ROE of 137.41% and net margin of 20.96%.
  • Revenue grew 5.8% year-over-year on continued demand.
  • Institutional investors increased stakes in the stock.
Risk Factors
  • SVP sold shares, dropping holdings 15% for $400k.
  • FY 2026 guidance ($21.70-$23.10) trails analyst avg ($22.38).
Bullish Signals
  • Amgen beat quarterly consensus estimates for both EPS ($5.15 vs $4.77) and revenue ($8.62B vs $8.58B), demonstrating strong operational execution.
  • The company achieved a robust return on equity of 137.41% and maintained a healthy net margin of 20.96%.
  • Revenue grew by 5.8% year-over-year, indicating continued demand for the company's biologic medicines in oncology and other therapeutic areas.
  • Multiple institutional investors, including Fort Washington Investment Advisors, Dogwood Wealth Management, and Anfield Capital Management, increased their stakes in the stock recently.
Risk Factors
  • SVP Nancy A. Grygiel sold a significant portion of her holdings (15% decrease) for $400,454, though insider ownership remains low at 0.85%.
  • The company's FY 2026 guidance range of $21.70-$23.10 EPS is slightly below the average analyst expectation of $22.38.
Bullish +65

Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential

📈 Piper Sandler reaffirms Overweight rating with $427 price target.

📈 Morgan Stanley maintains Overweight rating, raising target to $340.

💊 Dazodalibep Phase III trials conclude late 2026 for Sjogren's.

🔬 Amgen studies dazodalibep in moderate-to-severe symptoms and systemic disease.

🤝 Horizon acquisition bolsters Amgen's portfolio per Morgan Stanley.

📈 Piper Sandler reaffirmed an Overweight rating and $427 price target for Amgen Inc. (NASDAQ: AMGN).

📈 Morgan Stanley maintained its Overweight rating and increased its price objective to $340 from $332.

💊 Dazodalibep is a CD40 ligand-directed fusion protein for Sjogren's syndrome with Phase III trials concluding in late 2026.

🔬 Amgen is researching dazodalibep across two categories: moderate-to-severe symptoms and systemic disease activity.

🤝 Morgan Stanley notes that Amgen's portfolio is bolstered by its recent acquisition of Horizon.

⚖️ MariTide is identified as a major focus within Amgen's pipeline for obesity treatment.

🏢 Amgen Inc. was founded in 1980 and is headquartered in California.

Bullish Signals
  • Piper Sandler reaffirmed Overweight rating with $427 price target.
  • Morgan Stanley increased objective to $340 from $332.
  • Phase III conclusion for dazodalibep expected late 2026.
  • Horizon acquisition bolsters portfolio of cutting-edge medications.
  • MariTide highlighted as major obesity drug focus area.
Bullish Signals
  • Piper Sandler reaffirmed its Overweight rating with a $427 price target, signaling strong institutional confidence in the company's current valuation.
  • Morgan Stanley increased its price objective to $340 from $332, indicating a positive revision based on recent corporate developments.
  • The upcoming Phase III conclusion for dazodalibep in late 2026 represents a significant potential milestone for Amgen's immunology division.
  • Amgen's acquisition of Horizon is viewed as a strategic move to bolster its portfolio of cutting-edge medications.
  • MariTide is highlighted as a major focus area, suggesting strong analyst interest in the company's obesity drug potential.
Somewhat Bullish +45

Amgen (AMGN) Stock Could Be 2.1% Undervalued After Patent Verdict - simplywall.st

📉 Stock trades at $344.72, 2.1% undervalued vs $352.23 fair value.

⚖️ Jury verdict awards Harbour BioMed $20.2M for willful infringement.

📈 Delivered 30.33% return last year and 68.20% over three years.

💊 Pipeline features MariTide, Repatha, and oncology bispecific T-cell engagers.

⚠️ Revenue faces headwinds from pricing regulations and biosimilar competition.

📉 Amgen stock is trading at $344.72, representing a 2.1% undervaluation against a calculated fair value of $352.23.

⚖️ Harbour BioMed secured a jury verdict confirming willful infringement by Amgen and awarded $20.2 million in damages.

📈 Amgen has delivered a 30.33% total shareholder return over the past year and a 68.20% return over three years.

💊 The company's pipeline includes high-margin assets like MariTide for obesity, Repatha for cardiovascular disease, and bispecific T-cell engagers for oncology.

📉 Legal risks persist as the verdict highlights ongoing patent litigation exposure in the biopharmaceutical sector.

⚠️ Revenue faces potential headwinds from tightening drug pricing regulations and competition from biosimilars.

💰 Amgen maintains its status as an established dividend payer with a solid balance sheet structure.

Bullish Signals
  • Trading at $344.72, ~2.1% below fair value of $352.23.
  • Achieved 30.33% return last year and 68.20% over three years.
  • Late-stage pipeline includes high-margin products like MariTide and Repatha.
  • Established dividend payer with a solid balance sheet.
Risk Factors
  • Guilty of patent infringement, ordered to pay $20.2M damages.
  • Exposed to tightening drug pricing pressures impacting growth and margins.
Bullish Signals
  • Amgen stock is trading at $344.72, which is approximately 2.1% below the calculated fair value of $352.23, suggesting a potential buying opportunity.
  • The company has achieved a strong 30.33% total shareholder return over the last year and a 68.20% return over three years, indicating sustained investor confidence.
  • Amgen's late-stage pipeline features high-margin, first-in-class products including MariTide for obesity and Repatha for cardiovascular disease that are poised to drive future growth.
  • The company is classified as an established dividend payer with a solid balance sheet, providing resilience against market volatility.
Risk Factors
  • Amgen was found guilty of willful patent infringement by Harbour BioMed's jury and ordered to pay $20.2 million in damages.
  • Amgen is exposed to potential tightening of drug pricing pressures which could impact future top-line growth and margins.
Somewhat Bearish -25

Amgen faces Delaware patent verdict, shares under legal scrutiny - Ad-hoc-news.de

🏛️ Delaware jury found Amgen willfully infringed Harbour BioMed's patent in June 2026.

💰 Court awarded Harbour BioMed exactly $20,203,704 in damages for the infringement.

⚖️ Analysts warn US law permits enhancing damage award up to three times.

📉 Legal disputes over platform technologies flagged as key risk factor for Amgen stock.

💼 Majority of analysts still rate Amgen as Buy or Overweight despite verdict.

🏛️ A Delaware jury found Amgen willfully infringed Harbour BioMed's Grosveld antibody patent in June 2026.

💰 The court awarded Harbour BioMed exactly $20,203,704 in damages for the infringement.

⚖️ Analysts warn that US law permits enhancing the damage award up to three times due to willful infringement.

📉 Legal disputes over platform technologies are now flagged as a key risk factor for Amgen's stock.

💼 The majority of analysts still rate Amgen as Buy or Overweight despite the legal verdict.

📈 Analyst consensus shows double-digit expected earnings per share for the current fiscal year.

💊 Amgen generates revenue from mature therapies including Neulasta, Prolia, and Repatha.

📊 Shares traded at approximately $305 with a market cap of $164 billion as of June 2026.

🎯 The average 12-month price target among analysts is in the low $300 range.

Bullish Signals
  • Analysts maintain Buy or Overweight ratings despite legal losses.
  • Company maintains double-digit expected earnings per share this year.
  • Strong market position with stable revenue from mature drugs.
  • Shares traded at $305 showing sustained investor interest.
  • $164 billion market cap reflects S&P 500 leader status.
Risk Factors
  • Jury found willful infringement, exposing Amgen to up to three times initial award.
  • Analysts flag litigation and patent challenges as key stock risk factors.
  • Verdict forces reassessment of Amgen's IP risk profile and pipeline valuations.
  • Platform disputes could negatively impact collaboration economics with partners.
Bullish Signals
  • Majority of analysts maintain Buy or Overweight ratings on Amgen despite recent legal losses.
  • Company maintains double-digit expected earnings per share for the current fiscal year.
  • Amgen holds a strong market position with stable revenue from mature oncology and bone health drugs.
  • Shares traded at $305, indicating sustained investor interest in the biotech giant.
  • Market cap of $164 billion reflects its status as a large-cap S&P 500 leader.
Risk Factors
  • Jury found willful infringement of Harbour BioMed's patent, exposing Amgen to potential enhanced damages up to three times the initial award.
  • Analysts are explicitly flagging litigation and patent challenges as a key risk factor for the stock.
  • The legal verdict forces a reassessment of Amgen's intellectual property risk profile and long-term pipeline valuations.
  • Legal disputes over platform technologies could negatively impact collaboration economics with partners.
Slightly Bullish +15

Amgen Stock - Weekly outlook with earnings date and pipeline in view - Ad-hoc-news.de

📅 Earnings anticipated in late July 2026.

💰 Shares closed at $337.60 on June 18.

🏢 Market cap stands at approximately $181 billion.

💊 Revenue driven by Repatha, Prolia, and biosimilars.

🔬 Pipeline focuses on obesity, oncology, and inflammation.

📅 Amgen's next quarterly earnings are anticipated in late July 2026, though no official date has been released yet.

💰 Shares closed at $337.60 on June 18, 2026, with extended-hours trading showing a fractional decline to around $337.00.

🏢 The company holds a market capitalization of approximately $181 billion as of the latest reported close.

💊 Key revenue drivers include Repatha (cholesterol), Prolia (osteoporosis), and an expanding biosimilars portfolio.

🔬 Investors are monitoring pipeline catalysts in obesity, oncology, and inflammation for potential medium-term revenue shifts.

📊 Amgen is a constituent of both the S&P 500 and Nasdaq-100 indices.

🗣️ Management has identified obesity, cardiovascular disease, and oncology as primary growth pillars for future expansion.

Bullish Signals
  • Amgen market cap: $181 billion.
  • Blockbuster drugs: Repatha, Prolia.
  • Pipeline focus: Obesity, Oncology.
Risk Factors
  • Shares down in extended hours before earnings.
  • No official earnings date creates timing uncertainty.
Bullish Signals
  • Amgen maintains a substantial market capitalization of $181 billion, reflecting strong investor confidence in its biotechnology portfolio.
  • The company's diversified revenue stream includes established blockbuster drugs like Repatha and Prolia alongside a growing biosimilars business.
  • Pipeline focus on high-priority areas such as obesity (AMG 133) and oncology suggests potential for significant long-term growth catalysts.
Risk Factors
  • Shares traded fractionally lower in extended hours, suggesting cautious sentiment ahead of the upcoming earnings release.
  • No official earnings date has been posted yet, creating uncertainty regarding precise timing for investor expectations.
Slightly Bullish +25

Amgen Stock (AMGN) Opinions on Congressional Trade Disclosure - Quiver Quantitative

📈 Rep. David J. Taylor added Amgen shares in early June.

💰 Q1 2026 revenues reached $8.6 billion, up 5.76%.

📉 Executives sold shares four times with zero purchases recently.

🏛️ Rep. Maria Elvira Salazar traded $100,000 in congressional activity.

📊 Institutional investors diverged: Capital World added 6.2M shares.

📈 Representative David J. Taylor added Amgen shares to his portfolio in early June, signaling a preference for stable cash-flow generators.

💰 Amgen reported Q1 2026 revenues of $8.6 billion, marking a 5.76% increase from the prior year.

📉 Insider trading data shows executives have sold shares four times in the past six months with zero purchases.

🏛️ Congressional trading activity includes Representative Maria Elvira Salazar making one purchase and one sale totaling $100,000.

📊 Institutional investors show divergent views, with Capital World Investors adding 6.2M shares while Capital International removed 11M shares.

🎯 Analyst price targets range from a low of $327 by Truist Securities to a high of $427 by Piper Sandler.

📉 The median analyst price target for Amgen is set at $350.00 across 14 analysts in the last six months.

Bullish Signals
  • Amgen revenue grew 5.76% in Q1 2026 to $8.6 billion.
  • Rep. Taylor initiated Amgen as a stable cash-flow generator.
  • Capital World Investors added 26.8%, increasing holdings by 6M shares.
  • Geode Capital Management added 1.1M shares, up 7.9%.
  • Piper Sandler analyst set $427 price target for growth.
Risk Factors
  • Insiders sold $21M in six months with no buys.
  • Capital International cut holdings by 60.8% (11M shares).
  • JPMorgan reduced stakes by 45.8% (nearly 2M shares).
  • Rockefeller Capital exited 71.9% of its position.
  • Pacer Advisors completely exited with all 1.6M shares.
Bullish Signals
  • Amgen achieved a 5.76% revenue growth in Q1 2026, reaching $8.6 billion.
  • Representative David J. Taylor initiated new positions in Amgen, viewing it as a stable cash-flow generator.
  • Capital World Investors increased their position by 26.8%, adding over 6 million shares.
  • Geode Capital Management added 1.1 million shares to its portfolio, increasing holdings by 7.9%.
  • Piper Sandler analyst David Amsellem set a high price target of $427, indicating strong growth potential.
Risk Factors
  • Amgen insiders have executed four sales totaling over $21 million in the past six months with no purchases.
  • Capital International Investors significantly reduced their position by removing 11 million shares (-60.8%).
  • JPMorgan Chase & Co. decreased its holdings by 45.8%, removing nearly 2 million shares.
  • Rockefeller Capital Management L.P. cut its position by 71.9%, exiting a significant portion of its stake.
  • Pacer Advisors, Inc. completely exited its position, removing all 1.6 million shares held.
Bullish +75

Harbour BioMed Wins $20 Million Patent Verdict Against Amgen - Contract Pharma

🏛️ Delaware jury found Amgen liable for willful patent infringement against Harbour BioMed.

💰 Jury awarded $20.2 million damages for antibody technology infringement.

⚖️ Jurors unanimously upheld validity of Harbour's 'Grosveld' transgenic rodent patent.

📈 Willful infringement could triple damages to $60.6 million pending review.

🏆 Rare full victory for small biotech firm against major pharma in Delaware.

🏛️ A U.S. jury in Delaware found Amgen Inc. and subsidiary Teneobio liable for willful patent infringement against Harbour BioMed.

💰 The jury awarded Harbour BioMed $20.2 million in damages for the infringement of its antibody-discovery technology.

⚖️ Jurors unanimously upheld the validity of the 'Grosveld patent' covering Harbour's proprietary transgenic rodent platform.

📈 Due to a finding of willful infringement, potential damages could triple to approximately $60.6 million pending judicial review.

🧬 The dispute centers on technology used to generate fully human antibodies for treating cancer and immune diseases.

🏆 This marks a rare full victory for a smaller biotech firm against a major pharmaceutical company in Delaware.

🗣️ Harbour BioMed CEO Dr. Jingsong Wang called the decision an 'epic victory' reaffirming the company as the true innovator.

⚡ Amgen plans to pursue certain legal issues with the court during post-trial proceedings.

🌍 The verdict could reinforce legal protections for antibody-discovery platforms across the global biotechnology sector.

Bullish Signals
  • $20.2M jury verdict validates core IP and technology platform.
  • Unanimous patent validity finding deters future infringement by competitors.
  • Willful infringement ruling could triple damages to $60.6M.
  • Victory reaffirms Harbour as true innovator in antibody discovery.
  • Delaware win sets precedent for small biotech firms.
Risk Factors
  • Amgen pursuing legal issues post-trial, delaying resolution.
  • Damages could triple to $60.6 million.
  • Intensifying competition in multibillion-dollar antibody therapeutics market.
Bullish Signals
  • Harbour BioMed secured a decisive $20.2 million jury verdict against Amgen, validating its core intellectual property and technology platform.
  • The unanimous finding of patent validity strengthens Harbour's broader IP portfolio and deters future infringement attempts by large competitors.
  • The willful infringement ruling opens the possibility for damages to triple to roughly $60.6 million, significantly increasing potential financial recovery.
  • CEO Dr. Jingsong Wang highlighted that the victory reaffirms Harbour as the true innovator behind transformative antibody-discovery technology.
  • This rare win in Delaware sets a strong precedent for smaller biotechnology firms challenging major pharmaceutical companies over foundational patents.
Risk Factors
  • Amgen has indicated it will pursue certain legal issues during post-trial proceedings, suggesting the dispute may not be fully resolved immediately.
  • The potential for damages to triple to $60.6 million introduces uncertainty regarding the final financial outcome and timing of payments.
  • The case highlights intensifying competition over foundational technologies in the multibillion-dollar antibody therapeutics market.
Bullish +75

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

🏛️ European Commission approves tarlatamab for ES-SCLC after first-line chemo failure.

📉 Trial shows 40% lower death risk and 13.6 months median survival.

⚠️ Common side effects include CRS (56.7%) and neutropenia (16.9%).

🏛️ The European Commission has granted marketing authorization for Amgen's IMDYLLTRA® (tarlatamab) as a monotherapy for extensive-stage small cell lung cancer (ES-SCLC).

💊 This approval is specifically for adult patients requiring systemic therapy after disease progression on or after first-line platinum-based chemotherapy.

📉 The decision was based on the DeLLphi-304 Phase 3 trial, which showed a 40% reduction in the risk of death compared to standard-of-care chemotherapy.

⏳ Patients treated with IMDYLLTRA experienced a median overall survival of 13.6 months versus 8.3 months for those receiving chemotherapy alone.

🎯 IMDYLLTRA is the first and only T-cell engager therapy approved by the European Commission for the treatment of small cell lung cancer.

🔬 The drug works by binding to DLL3 on tumor cells and CD3 on T cells, activating T cells to kill cancer cells expressing the DLL3 protein.

⚠️ Cytokine release syndrome (CRS) was the most common adverse reaction, occurring in 56.7% of patients, primarily after the first two doses.

🧠 Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 4.7% of patients and can occur up to several weeks after administration.

🩸 Neutropenia was reported in 16.9% of patients, with grade 3 or 4 events occurring in 8.2% of the study population.

⚖️ The safety profile was consistent with known risks for this class of therapy, including serious infections and elevated liver enzymes.

🏥 Patients must be monitored from the start of infusion for 6 to 8 hours on Cycle 1 Day 1 and Day 8 in an appropriate healthcare setting.

💉 The recommended dosing schedule involves an initial dose of 1 mg on day 1 followed by 10 mg on days 8, 15, and every 2 weeks thereafter.

👩‍⚕️ Physicians experienced in cancer therapy must supervise the administration of IMDYLLTRA to manage severe reactions like CRS and neurologic toxicity.

🤝 Amgen's broader DeLLphi clinical program continues to evaluate tarlatamab in combination regimens and earlier stages of SCLC.

📰 Results from the pivotal DeLLphi-304 trial were previously presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine.

Bullish Signals
  • EC approved IMDYLLTRA® for ES-SCLC post-chemotherapy.
  • DeLLphi-304 trial cut death risk by 40%.
  • Median survival extended to 13.6 vs 8.3 months.
  • First T-cell engager therapy approved in Europe.
  • Targets DLL3 protein in up to 96% of patients.
Risk Factors
  • CRS occurred in 56.7% of patients; fatal cases reported.
  • Neurologic toxicity (ICANS) affected 65%; one fatal case.
  • Treatment discontinuation required for 0.6% due to CRS.
  • Serious infections including fatal cases reported with IMDYLLTRA.
  • Elevated liver enzymes in 39-43%; Grade 3/4 events rare.
  • Cytopenias common: neutrophils down 16%, platelets down 30%.
  • Requires specialized facility for monitoring severe reactions.
  • Patients must stay near facility 48 hours post-infusion.
  • Hypersensitivity reactions including bronchospasm reported.
Bullish Signals
  • The European Commission has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after first-line platinum-based chemotherapy.
  • The approval is based on the DeLLphi-304 Phase 3 trial, which demonstrated a significant survival benefit over standard of care chemotherapy, reducing the risk of death by 40% and extending median overall survival by more than five months (13.6 vs. 8.3 months).
  • IMDYLLTRA® is the first and only T-cell engager therapy approved to treat small cell lung cancer in Europe, marking a major milestone for patients with this aggressive disease.
  • The drug targets DLL3, a protein expressed on the surface of SCLC cells in up to 96% of patients, while being minimally expressed on healthy cells, offering a highly specific mechanism of action.
  • Amgen's robust clinical development program includes multiple ongoing Phase 3 studies (DeLLphi-303 through DeLLphi-313) evaluating IMDYLLTRA in earlier stages of SCLC and as part of combination regimens.
  • Results from the pivotal DeLLphi-304 study were reviewed at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine, validating the drug's efficacy in a global setting.
  • The safety profile was consistent with known characteristics, with manageable adverse reactions such as cytokine release syndrome (CRS) occurring primarily after the first two doses and resolving with appropriate monitoring and supportive care.
Risk Factors
  • Cytokine release syndrome (CRS) occurred in 56.7% of patients, with serious CRS events reported in 19.7%, and fatal CRS cases have been reported in the post-marketing setting.
  • Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred in 65% of patients, with life-threatening or fatal reactions reported, including one fatal ICANS case.
  • Treatment discontinuation due to CRS was required for 0.6% of patients, and treatment interruption or dose modification occurred in 2.1% of patients.
  • Serious infections, including life-threatening and fatal infections, have been reported in patients treated with IMDYLLTRA, with opportunistic infections occurring in 43% of the pooled safety population.
  • Hepatotoxicity was observed in the pooled safety population, with elevated ALT in 39% of patients and elevated AST in 43%, including Grade 3 or 4 events in 2.5% and 3.2% respectively.
  • Cytopenias are a significant risk, with decreased neutrophils occurring in 16% of patients (including 8.2% Grade 3 or 4) and decreased platelets in 30% (including 2.2% Grade 3 or 4).
  • The drug requires administration in an appropriate healthcare facility equipped to monitor and manage severe reactions like CRS and ICANS, limiting accessibility for patients.
  • Patients must remain within proximity of a healthcare facility for up to 48 hours following initial infusions, imposing logistical burdens on caregivers and patients.
  • Hypersensitivity reactions, including rare severe events such as bronchospasm, have been reported in patients treated with IMDYLLTRA.
Somewhat Bullish +50

The Zacks Analyst Blog Highlights RTX, Wells Fargo, Amgen, Daily Journal and Tandy Leather

📅 Zacks highlights RTX, Wells Fargo, Amgen, Daily Journal, and Tandy Leather on May 27, 2026.

✈️ RTX gained +33.7% with a $271B backlog despite tariff risks in the aerospace sector.

🏦 Wells Fargo lagged peers due to slow income recovery but plans fee-based business scaling.

💊 Amgen outperformed with key drug sales offset by biosimilar competition and pipeline focus.

💻 Daily Journal shifted to software revenue, gaining +12.2% despite legacy publishing margin pressure.

📅 Zacks.com announced its Analyst Blog highlights on May 27, 2026, featuring stocks including RTX, Wells Fargo, Amgen, Daily Journal, and Tandy Leather.

✈️ RTX Corp. shares outperformed the aerospace-defense industry over the past year with a +33.7% gain versus +3.5%.

🛡️ The company secured ample orders for defense products from the Pentagon and allies while commercial air traffic improved sales.

📦 Strong volumes in large commercial engines and Pratt Canada operations helped RTX register a $271 billion backlog as of March 31, 2026.

⚠️ U.S. government import tariffs and supply-chain challenges pose risks that could adversely impact the aerospace sector.

🏦 Wells Fargo shares gained +6.4% over the past year but lagged the financial investment banking industry's +26.3% gain.

💰 The bank's net interest income recovery remains slow despite an expected Fed rate cut in 2026, pressuring revenue growth.

📉 Mortgage banking income is weak due to ongoing volatility in mortgage rates and a lower return on equity indicating reduced efficiency.

📈 Earnings surpassed estimates in three of the trailing four quarters as the removal of the asset cap allows deposit and loan growth.

🚀 Wells Fargo plans to scale fee-based businesses while enhancing its revenue mix with strong capital and liquidity support.

💊 Amgen Inc. shares outperformed the medical-biomedical industry over the past year with a +24.8% gain versus +22.3%.

🧬 The biotech company beat first-quarter estimates for both earnings and sales driven by key medicines like Evenity, Repatha, and Uplizna.

📉 Sales of best-selling drugs Prolia and Xgeva will decline sharply in 2026 due to biosimilar launches and upcoming LOE cliffs.

🧬 Amgen has several key pipeline assets with a primary focus on the obesity candidate MariTide to offset declining revenues.

📰 Daily Journal Corp. shares gained +12.2% over the past year against the publishing industry's +24.9% gain.

💻 This microcap company is evolving into a software-driven business with Journal Technologies contributing approximately 79% of total revenue in FY26.

🌍 The company's expanding presence across 37 states and international markets reflects growing adoption of its government-focused software solutions.

💰 Daily Journal maintains a highly liquid balance sheet with positive operating cash flow and reduced margin debt.

⚠️ Legacy publishing operations face structural margin pressure from rising costs, while elevated legal expenses limit operating leverage.

Bullish Signals
  • Amgen shares rose +24.8%, outperforming the Zacks Medical industry.
  • Company beat Q1 earnings and sales estimates.
  • Key drugs like Evenity and Repatha drive sales growth.
  • Biosimilar launches offset declines from mature products.
  • Pipeline focus on obesity candidate MariTide offers upside.
Risk Factors
  • Amgen sales drop 2026 due to biosimilar launches for Prolia and Xgeva.
  • Pipeline setbacks and LOE cliffs threaten Amgen revenue growth.
  • Price cuts and competition hurt Amgen key product sales.
  • Wells Fargo net interest income recovery stays slow despite 2026 Fed rate cut.
  • Mortgage banking income weak amid volatile mortgage rates at Wells Fargo.
Bullish Signals
  • Amgen's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year, rising +24.8% compared to the industry's +22.3% gain.
  • The company beat first-quarter estimates for both earnings and sales, demonstrating strong operational performance.
  • Key medicines including Evenity, Repatha, Uplizna, Imdelltra, Tavneos, and Tezspire are driving sales growth.
  • New biosimilar launches are contributing to top-line growth, offsetting declines from mature products.
  • Amgen has several key pipeline assets with a primary focus on the obesity candidate, MariTide, offering significant upside potential.
Risk Factors
  • Amgen faces sharp sales declines for best-selling drugs Prolia and Xgeva in 2026 due to biosimilar launches.
  • Recent pipeline setbacks and upcoming loss-of-exclusivity (LOE) cliffs pose significant concerns for Amgen's future revenue growth.
  • Price declines and increased competition are actively hurting sales of some of Amgen's key products.
  • Wells Fargo's net interest income recovery may remain slow despite the expected Fed rate cut in 2026, which is pressuring revenue growth.
  • Mortgage banking income remains weak amid ongoing volatility in mortgage rates for Wells Fargo.
  • The lower return on equity at Wells Fargo indicates less efficiency in using its shareholders' funds.
  • RTX faces risks from uncertainties created by recent U.S. government-issued import tariffs affecting the aerospace sector.
  • Supply-chain challenges continue to affect the aerospace sector, which may adversely impact RTX's operations.
Slightly Bullish +25

Amgen Shareholders Reaffirm Board, Pay and Auditors

📅 Shareholders re-elected all directors and approved executive compensation at the May 2026 meeting.

❌ Proposal for an independent board chair failed, preserving current leadership structure.

⚖️ Analysts rate AMGN Buy ($427 target) despite high leverage and mixed valuation views.

💰 Company boasts strong margins, durable cash flow, a 3.0% dividend yield, and a 26.1 P/E.

🧬 Amgen is a global biotech leader in oncology, cardiovascular disease, and inflammation therapeutics.

📅 At its annual meeting on May 19, 2026, Amgen shareholders re-elected all 12 director nominees to one-year terms.

✅ Shareholders approved the company's executive compensation program on an advisory basis.

🧾 Investors ratified Ernst & Young LLP as Amgen's independent registered public accountants for fiscal year ending December 31, 2026.

❌ A shareholder proposal requiring an independent board chair failed, preserving the existing leadership structure.

📈 The most recent analyst rating on AMGN stock is a Buy with a $427.00 price target.

⚖️ Spark's AI Analyst rates AMGN as Neutral due to mixed valuation and high leverage despite strong fundamentals.

💰 Amgen scores well on core operating fundamentals including strong margins and durable free cash flow.

📉 High leverage on the balance sheet and weak technical momentum are holding back the overall score.

📊 The company has a P/E ratio of 26.1 with an approximate 3.0% dividend yield.

🧬 Amgen is a global biotechnology company focused on discovering, developing, and manufacturing innovative human therapeutics.

🎯 Key therapeutic areas include oncology, cardiovascular disease, inflammation, and other serious illnesses.

🌍 The company markets biologic and biosimilar medicines worldwide targeting both specialty and primary care markets.

🏭 Amgen leverages its research capabilities and large-scale biologics manufacturing infrastructure.

Bullish Signals
  • Amgen re-elected all 12 directors ensuring leadership continuity.
  • Shareholders approved executive compensation signaling investor support.
  • Investors ratified Ernst & Young as independent auditors.
  • Analysts rate AMGN Buy with $427.00 price target.
  • Strong margins and durable free cash flow fundamentals.
  • Raised full-year guidance supports positive earnings setup.
Risk Factors
  • High leverage holds back overall stock score.
  • Weak technical momentum for AMGN.
  • Mixed valuation: P/E 26.1, 3.0% yield.
Bullish Signals
  • Amgen stockholders re-elected all 12 director nominees, ensuring continuity in board leadership and governance.
  • Shareholders approved the company's executive compensation program on an advisory basis, signaling continued investor support for current pay practices.
  • Investors ratified Ernst & Young LLP as Amgen's independent registered public accountants, reinforcing stability in the company's audit oversight.
  • The most recent analyst rating on AMGN stock is a Buy with a $427.00 price target.
  • AMGN scores well on core operating fundamentals including strong margins and durable free cash flow.
  • The company is supported by a positive earnings-call setup with raised full-year guidance.
Risk Factors
  • The overall stock score is held back primarily by high leverage on the balance sheet.
  • Technical momentum for AMGN is described as weak.
  • Valuation metrics are mixed, with a P/E ratio of 26.1 and only a ~3.0% dividend yield.
Slightly Bearish -10

Are Options Traders Betting on a Big Move in Amgen Stock?

📊 Amgen May 2026 options show highest implied volatility in the equity market.

⚙️ High volatility suggests investors expect significant upcoming price movement or catalysts.

📉 Mixed analyst sentiment lowered Zacks estimates from $5.81 to $5.64.

📊 Amgen stock options with a May 15, 2026 $200 strike price are exhibiting the highest implied volatility among all equity options today.

⚙️ High implied volatility typically signals that investors anticipate significant future price movement or an upcoming catalyst event.

📉 Analyst sentiment is currently mixed, with five analysts lowering earnings estimates while only one raised them for the current quarter.

🔄 These recent analyst adjustments have lowered Zacks Consensus Estimate per share from $5.81 to $5.64.

🔬 Amgen holds a Zacks Rank #3 (Hold) rating and ranks in the bottom 40% of its Medical-Biomedical and Genetics industry sector.

💰 Options traders may be targeting this high implied volatility to sell premium and capture time decay if the stock does not move significantly.

📈 The article concludes by promoting Zacks Investment Research's independent tools and rankings rather than providing a definitive price target for Amgen.

Bullish Signals
  • Amgen options priced for major movement by May 2026.
  • Zacks elite stocks beat market 2X with 23.9% annual gain.
  • Zacks tools built on history of 23.89% annual returns since 1988.
Risk Factors
  • Ranks bottom 40% vs medical peers.
  • Hold rating (Zacks Rank #3).
  • Five analysts cut quarter estimates.
  • Consensus estimate declined to $5.64.
  • May '26 options hint at major sell-off.
Bullish Signals
  • Options traders are pricing in significant movement for Amgen stock, as evidenced by the May 15, 2026 $200 Call having some of the highest implied volatility among all equity options today.
  • Since 1988, Zacks Investment Research's list of elite stocks has beaten the market more than 2X over with an average gain of +23.9% per year, suggesting potential for early price pops in selected tickers.
  • Zacks Investment Research offers tools like the Price Response Indicator and Earnings ESP to help investors succeed, built on a history of averaging +23.89% annual returns since 1988.
Risk Factors
  • Amgen Inc. (AMGN) currently holds a Zacks Rank #3, indicating a 'Hold' rating, and ranks in the bottom 40% of its medical industry peers.
  • Over the last 30 days, five analysts have dropped their earnings estimates for the current quarter, while only one increased them.
  • This negative sentiment among analysts has caused the Zacks Consensus Estimate for the current quarter to decline from $5.81 per share to $5.64 per share.
  • High implied volatility in the May 15, 2026 $200 Call options suggests a market expectation of a large move that could result in a significant sell-off rather than a rally.
Neutral 0

Are Options Traders Betting on a Big Move in Amgen Stock?

📈 High IV on AMGN options suggests investors expect significant price movement.

🏥 Amgen holds a Bottom 40% Zacks Rank within its industry sector.

📉 Analyst consensus lowered quarterly earnings estimate from $5.81 to $5.64.

📊 Options traders are pricing in significant movement for Amgen Inc. (AMGN) stock, indicated by the May 15, 2026 $200 Call option having among the highest implied volatility levels today.

📉 High implied volatility typically suggests investors anticipate a substantial price change due to upcoming events or fundamental shifts in one direction.

🏥 Currently, Amgen holds a Zacks Rank #3 (Hold) within the Medical - Biomedical and Genetics industry, placing it in the Bottom 40% of its industry rank.

📝 Analyst sentiment is mixed regarding earnings estimates for the current quarter; one analyst increased their projection while five reduced theirs.

💰 The net impact of these changes lowered the Zacks Consensus Estimate for the current quarter from $5.81 per share to $5.64 per share.

💸 Experienced options traders often seek high implied volatility opportunities to sell premium and capture time decay rather than betting on a price increase.

⚠️ The strategy of selling options relies on the underlying stock not moving as much as originally expected by expiration.

📰 This analysis originates from Zacks Investment Research, which offers additional reports including "7 Best Stocks for the Next 30 Days" and free stock analysis reports for Amgen.

Bullish Signals
  • Options traders price significant Amgen movement.
  • Analyst increased current quarter earnings estimates.
  • Amgen listed as best stock for 30 days.
Risk Factors
  • Amgen ranks Bottom 40% of industry with weak performance.
  • Five analysts dropped estimates versus only one increase recently.
  • Quarterly profit estimate fell from $5.81 to $5.64.
Bullish Signals
  • Options traders are pricing in significant future movement for Amgen, potentially indicating upcoming positive catalysts that could drive a rally.
  • One analyst recently increased earnings estimates for the current quarter, suggesting some market optimism remains.
  • Amgen has been recognized in Zacks Investment Research's report of '7 Best Stocks for the Next 30 Days', highlighting its potential inclusion among top investment opportunities.
Risk Factors
  • Amgen is currently ranked as a Zacks Rank #3 (Hold) and sits within the Bottom 40% of its Medical - Biomedical and Genetics industry, indicating weak relative performance.
  • Analyst sentiment has turned negative with five analysts dropping their earnings estimates versus only one increase over the last 30 days.
  • The revised Zacks Consensus Estimate for the current quarter has fallen from $5.81 per share to $5.64, reflecting diminished profit expectations.
Bullish +75

Nicholas Company Inc. Acquires New Position in Amgen Inc. $AMGN

📈 Institutional investors increased holdings significantly while SVP Nancy Grygiel reduced her stake.

💰 Q1 revenue rose 5.8% to $8.62 billion with EPS beating estimates by $0.38.

📊 Stock trades at a 3.0% yield with a P/E ratio of 23.08.

📈 Nicholas Company Inc. increased its Amgen stake by acquiring 16,415 shares valued at $5.37 million in the fourth quarter.

🏢 Robeco Institutional Asset Management B.V. grew its Amgen holdings by 10% to own 481,453 shares worth $157.58 million.

📊 Sequoia Financial Advisors LLC increased its position by 2.3%, now holding 160,646 shares valued at $45.33 million.

💰 Curtis Advisory Group LLC established a new position in Amgen worth approximately $1.67 million during the fourth quarter.

📈 Global Wealth Management Investment Advisory Inc. significantly expanded its stake by 56.2% to own shares totaling $3.68 million.

🔄 Jones Financial Companies Lllp grew its holdings by 18.2%, adding 6,115 shares for a total value of $10.89 million.

🏛️ Institutional investors collectively control 76.50% of Amgen's outstanding stock as of the latest filings.

📉 SVP Nancy A. Grygiel sold 1,237 shares worth $400,454 on May 4th, reducing her direct ownership by 15%.

💹 Shares of Amgen opened at $331.70 and are currently trading with a market capitalization of $179.01 billion.

📉 The stock trades at a P/E ratio of 23.08 with a beta of 0.44, indicating lower volatility compared to the broader market.

🏆 Amgen reported Q1 earnings of $5.15 per share, surpassing analyst estimates of $4.77 by $0.38.

💰 The company generated revenue of $8.62 billion for the quarter, up 5.8% from the prior year period.

🎯 Amgen provided FY 2026 EPS guidance ranging between $21.70 and $23.10 for the current fiscal year.

💵 A quarterly dividend of $2.52 per share will be paid to investors of record on May 15th, with an ex-dividend date of May 15th.

🔄 The total annualized dividend is projected at $10.08 per share, resulting in a current yield of 3.0%.

Bullish Signals
  • EPS beat estimates at $5.15 vs $4.77 consensus.
  • Revenue grew 5.8% YoY to reach $8.62 billion.
  • Net margin hit robust 20.96% with ROE of 137.41%.
  • Investors increased stakes, including Nicholas Company and Robeco.
  • Set full-year 2026 EPS guidance between $21.70-$23.10.
  • Initiated quarterly dividend of $2.52 for a 3.0% yield.
  • Mkt cap is $179.01B with attractive P/E/G of 3.33.
Risk Factors
  • High debt-to-equity of 5.65 amplifies potential losses.
  • Stock trades below $355.12 50-day average, showing bearish sentiment.
  • Insider Nancy Grygiel sold 1,237 shares, signaling concern.
  • Dividend payout ratio of 70.15% limits capital flexibility.
  • Management guidance trails analyst FY 2026 EPS expectations.
Bullish Signals
  • Amgen reported $5.15 earnings per share for the quarter, significantly beating analysts' consensus estimates of $4.77 by $0.38.
  • The company generated revenue of $8.62 billion, exceeding analyst expectations of $8.58 billion, marking a 5.8% year-over-year growth.
  • Amgen achieved a robust net margin of 20.96% and an impressive return on equity of 137.41%.
  • Multiple institutional investors increased their stakes, with Nicholas Company Inc., Robeco Institutional Asset Management B.V., and Global Wealth Management Investment Advisory Inc. growing or initiating positions in the fourth quarter.
  • The company has established a strong future outlook by setting full-year 2026 guidance for earnings per share between $21.70 and $23.10, while analysts anticipate $22.36.
  • Amgen initiated a quarterly dividend of $2.52 per share to be paid on June 5th, offering an attractive annualized yield of 3.0%.
  • With a market capitalization of $179.01 billion and a P/E/G ratio of 3.33, the stock presents favorable valuation metrics relative to growth expectations.
Risk Factors
  • Amgen Inc (NASDAQ: AMGN) shows a debt-to-equity ratio of 5.65, indicating significant leverage that could amplify losses in adverse market conditions.
  • The stock price opened at $321.70 on Monday, while trading well below its 50-day moving average of $355.12, suggesting bearish short-term sentiment.
  • SVP Nancy A. Grygiel sold 1,237 shares representing a 15.00% decrease in her direct ownership, signaling potential insider concern about the stock's near-term prospects.
  • With an annualized dividend of $10.08 per share and a payout ratio of 70.15%, Amgen has limited flexibility to return capital during periods of financial stress.
  • Analyst expectations for FY 2026 EPS stand at $22.36, yet the company's own guidance is lower (21.700-23.100), suggesting management sees a challenging outlook compared to market consensus.
Bullish +60

Amgen stock (US0311621009): Pharma giant navigates C ... - ad-hoc-news

📈 Amgen reports Q1 2026 growth with broad portfolio resilience.

🔬 Company leverages biologics in oncology, cardiology, and neuroscience markets.

⚡ CTO David Reese retires as part of strategic leadership transitions.

🌎 Nasdaq-listed giant maintains influence despite intense healthcare sector competition.

⚠️ Investors should note stock volatility; this is not financial advice.

📊 Amgen reported first-quarter 2026 earnings on April 30, demonstrating broad-based growth across its portfolio.

💊 The pharmaceutical giant's results highlight sustained momentum despite intense competition in the healthcare sector.

🧬 Amgen operates as one of the world's largest independent biotechnology companies with a diverse therapeutic portfolio.

🔬 Its business model focuses on biologics derived from living cells, supported by significant R&D and manufacturing infrastructure.

🌎 The company develops therapeutics in key areas including oncology, cardiovascular disease, inflammation, bone health, and neuroscience.

👔 Chief Technology Officer David Reese announced his retirement as part of broader C-suite leadership changes.

⚡ Executing these transitions alongside strong earnings suggests management confidence in succession planning and strategic continuity.

📈 The broad-based expansion signals resilience in Amgen's product portfolio and market positioning during the quarter.

🇺🇸 As a Nasdaq-listed company, Amgen remains a significant player influencing the American pharmaceutical sector.

🔄 Leadership changes at this scale often signal potential shifts in research direction and innovation focus for the firm.

⚠️ Investors are advised that stocks are volatile and that this content does not constitute investment advice.

Bullish Signals
  • Amgen reported first-quarter 2026 earnings on April 30.
  • Sustained momentum with resilient product and market positioning.
  • Executed C-suite transitions alongside strong quarterly results.
  • Diversified portfolio spans oncology, cardiovascular disease, and more.
Risk Factors
  • Retiring CTO David Reese risks disrupting R&D continuity.
  • C-suite transition introduces near-term leadership uncertainty.
  • Lacks specific revenue or earnings figures for growth claims.
Bullish Signals
  • Amgen reported first-quarter 2026 earnings on April 30, showcasing broad-based growth across its portfolio.
  • The results underscore the company's ability to sustain momentum in a competitive market with resilient product and market positioning.
  • Management confidently executed significant C-suite transitions alongside strong quarterly results, signaling confidence in the company's trajectory and succession planning.
  • Amgen is one of the world's largest independent biotechnology companies with a diversified portfolio spanning oncology, cardiovascular disease, inflammation, bone health, neuroscience, and other therapeutic areas.
Risk Factors
  • The retirement of Chief Technology Officer David Reese signals potential shifts in strategic priorities, research direction, and innovation focus that could disrupt R&D continuity.
  • C-suite transitions are common but introduce near-term uncertainty regarding leadership stability and immediate decision-making processes.
  • While the article mentions 'broad-based growth', it does not provide specific revenue or earnings figures to substantiate the magnitude of performance relative to analyst expectations.
Slightly Bearish -10

Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

📉 Stock dropped 1.4% recently despite major indices posting gains.

💰 Analysts project EPS of $4.74 with a slight year-over-year decline.

📊 Valuation shows a discount P/E but a high PEG ratio.

📉 Amgen stock closed at $361.13, dropping 1.4% while major indices like the S&P 500 and Nasdaq posted gains.

🔍 The company's shares have fallen an additional 0.8% over the last month, outperforming the sector's broader decline.

💰 Analysts expect earnings per share of $4.74 for the upcoming quarter, representing a projected 3.27% year-over-year decrease.

📈 Revenue is forecast to hit $8.51 billion for the quarter, with a full-year target of $37.86 billion showing slight growth.

🛠 The Zacks Consensus EPS estimate has adjusted slightly lower by 0.15% recently based on short-term business trends.

📊 Amgen currently holds a Zacks Rank of #3 (Hold), which is neutral compared to the Strong Buy or Sell categories.

💵 The stock trades at a Forward P/E ratio of 16.48, trading at a discount relative to the industry average of 18.95.

📉 A PEG ratio of 3.65 is significantly higher than the sector average of 1.54, reflecting differences in earnings growth expectations.

🏭 The Medical - Biomedical and Genetics industry ranks in the bottom 43% across all tracked industries by Zacks metrics.

🔮 Zacks Investment Research encourages investors to monitor these valuation and estimate revision metrics for upcoming trading sessions.

Bullish Signals
  • Revenue expected to grow 4.42% year-over-year next quarter.
  • Full-year revenue projected to increase 3.02% over last year.
  • Stock trades at forward P/E of 16.48, below industry average.
  • Holds Zacks Rank #3 with strong top-rated industry history.
Risk Factors
  • Stock fell -1.4% while major indices rose.
  • Shares dropped 0.8% monthly vs 4.79% sector loss.
  • Analysts forecast a 3.27% year-over-year EPS decline.
  • EPS estimates fell 0.15%, signaling waning confidence.
  • Zacks Rank #3 places stock in bottom 43%.
  • Weak relative strength compared to top industries.
Bullish Signals
  • Amgen's revenue is projected to grow 4.42% year-over-year in the upcoming quarter, with analysts expecting $8.51 billion in total revenue.
  • Full-year consensus estimates indicate that Amgen's earnings and revenue are both expected to increase by 1.74% and 3.02%, respectively, compared to last year.
  • The stock is currently trading at a Forward P/E ratio of 16.48, which represents a discount compared to the industry average Forward P/E of 18.95.
  • Amgen holds a Zacks Rank of #3 (Hold), and historically, stocks in the top-rated industries have outperformed bottom industries by a factor of 2 to 1.
Risk Factors
  • Amgen's stock has underperformed the broader market, falling -1.4% while the S&P 500 rose and the Nasdaq increased 0.47%.
  • Shares have declined 0.8% over the last month, trailing the wider medical sector loss of 4.79% and the S&P 500's broader decline.
  • Analysts anticipate a 3.27% year-over-year drop in earnings per share (EPS) to $4.74 upon its upcoming earnings release.
  • The Consensus EPS estimate has decreased by 0.15% over the past month, reflecting waning analyst confidence or deteriorating business trends.
  • Amgen holds a Zacks Rank of #3 (Hold), whereas top-ranked industries historically outperform the bottom half by a factor of 2 to 1.
  • The Medical - Biomedical and Genetics industry ranks in the bottom 43% among all industries, suggesting limited relative strength compared to peers.
Bullish +75

RPRX vs. AMGN: Which Stock Is the Better Value Option?

📊 Zacks ranks Royalty Pharma as a Buy and Amgen as a Hold.

💰 Royalty Pharma offers lower forward P/E, PEG, and significantly lower P/B ratios.

🏆 RPRX earns a B grade for value while AMGN receives a C grade.

📊 Both Royalty Pharma (RPRX) and Amgen (AMGN) are highlighted as options within the Medical-Biomedical and Genetics sectors.

🏆 Zacks Investment Research evaluates stocks by pairing Style Scores with their Zacks Rank to identify value opportunities.

💼 Royalty Pharma currently holds a Zacks Rank of #2 (Buy), indicating a positive earnings outlook revision.

⚖️ Amgen holds a Zacks Rank of #3 (Hold), reflecting a more neutral stance on its recent earnings estimates.

📉 RPRX has a forward Price-to-Earnings (P/E) ratio of 9.92, significantly lower than AMGN's 14.84.

🧮 The PEG ratio for RPRX is 3.22, while AMGN’s stands slightly higher at 3.35.

📚 Royalty Pharma has a Price-to-Book (P/B) ratio of 3 compared to Amgen's much higher 19.35.

🏅 These valuation metrics contribute to RPRX receiving a "B" grade in the Value category of Style Scores.

⚠️ Amgen currently holds a "C" grade in the Value category due to its higher relative valuations.

📈 Analysts conclude that RPRX is likely the superior value option based on these combined metrics and rankings.

📄 Free stock analysis reports are available for both companies via Zacks Investment Research.

Bullish Signals
  • Amgen holds a Zacks Rank of #3 indicating neutral-to-positive trajectory.
  • Forward P/E ratio stands at 14.84 offering key valuation context.
  • Value grade C identifies Amgen as undervalued by earnings yield.
Risk Factors
  • Analysts hold Amgen on Zacks Rank #3 due to cautious earnings outlook.
  • Amgen received a lower Value grade of C compared to Royalty Pharma.
  • Forward P/B ratio of 19.35 signals high valuation vs Royalty Pharma's 3.0.
  • Higher PEG ratio of 3.35 reflects slower growth or elevated multiples.
Bullish Signals
  • Amgen currently holds a Zacks Rank of #3 (Hold), indicating a neutral-to-positive earnings estimate trajectory for the pharmaceutical giant.
  • The analysis notes that Amgen has a forward P/E ratio of 14.84, which provides a valuation metric for investors to consider alongside its cash flow and book value per share.
  • With a Value grade of C from the Style Scores system, Amgen is identified as an undervalued company by key metrics including earnings yield and cash flow per share.
Risk Factors
  • Amgen has been assigned a 'Hold' rating with a Zacks Rank of #3, suggesting analysts are cautious about its recent earnings estimates and outlook.
  • Amgen received a lower Value grade of C compared to Royalty Pharma's B grade, indicating it may be less attractive to value investors based on traditional metrics like P/E ratio and earnings yield.
  • The company's forward P/B ratio of 19.35 is significantly higher than Royalty Pharma's 3.0, which could signal that the market perceives Amgen as less undervalued relative to its book value.
  • Amgen has a higher PEG ratio of 3.35 compared to Royalty Pharma's 3.22, potentially reflecting slower expected earnings growth or higher valuation multiples that warrant scrutiny.
Bullish +75

Amgen adds $300M in Puerto Rico, nearing $1B total

Amgen invests $300M in its Juncos, Puerto Rico biologics facility.

Total U.S. manufacturing pledges now approach $2 billion.

Expansion creates advanced roles and strengthens domestic supply chains.

🏭 Amgen announced a new $300 million investment to expand its biologics manufacturing facility in Juncos, Puerto Rico.

🌍 The Juncos site was established in 1992 and currently produces medicines distributed to more than 60 countries.

💵 This new commitment brings the total planned investment on the island to nearly $1 billion over the past year.

🇺🇸 Amgen's broader U.S. manufacturing pledges now total nearly $2 billion with this latest addition.

📈 The expansion aims to increase production capacity, create advanced manufacturing roles, and generate hundreds of construction jobs.

⚙️ The investment will support next-generation manufacturing technologies and strengthen the company's domestic supply chain.

💬 CEO Robert Bradway stated the expansion reflects Amgen's continued commitment to American manufacturing and supporting the long-term strength of the supply chain.

🤝 The $300 million investment follows a previous $650 million commitment for the same Puerto Rico site.

📍 Amgen also has significant investments in Ohio ($900 million), California ($600 million for a science and innovation center), and North Carolina (more than $1.5 billion).

🏛️ Local officials, including Governor Jenniffer González, praised the investment as a testament to Puerto Rico's excellence and skilled workforce in biopharmaceuticals.

🔍 The move comes amid industry-wide efforts by global drugmakers to increase U.S. manufacturing capacity in response to tariff policy proposals.

💊 Expanding domestic production is expected to ensure patients have continued access to essential medicines.

🏗️ Secretary Sebastián Negrón highlighted that the total nearly $1 billion investment represents strong confidence in Puerto Rico's capabilities for producing life-saving medicines.

Bullish Signals
  • Amgen invests an additional $300 million in Juncos.
  • Total island investment reaches nearly $1 billion.
  • Expansion adds hundreds of construction jobs.
  • Facility produces medicines for over 60 countries.
  • Commitment strengthens domestic supply chain confidence.
Risk Factors
  • Amgen faces regulatory risks from new pharmaceutical tariff policies.
  • $300M Puerto Rico investment adds operational complexity to strategy.
  • Heavy capital spending may strain balance sheet and hurt profitability.
Bullish Signals
  • Amgen announced an additional $300 million investment to expand its biologics manufacturing facility in Juncos, Puerto Rico.
  • The new commitment brings the company's total planned investment on the island to nearly $1 billion over the past year.
  • This expansion will significantly increase production capacity and generate hundreds of construction jobs.
  • Amgen stated the investment supports advanced manufacturing roles and strengthens its domestic supply chain.
  • With this new facility, Amgen will continue to produce medicines distributed to more than 60 countries worldwide.
  • The $300 million commitment represents nearly $1 billion in confidence in Puerto Rico's workforce, capabilities, and infrastructure for biomanufacturing.
Risk Factors
  • Amgen faces significant regulatory and operational risks as it navigates the complex tariff policy proposals affecting pharmaceutical imports, particularly with its new $300M investment in Puerto Rico.
  • The company's heavy capital expenditure strategy, nearing $1 billion for Puerto Rico and nearly $2 billion total for U.S. manufacturing pledges, raises concerns about near-term profitability and balance sheet strain.
Slightly Bullish +25

Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

📉 Analysts are divided on Amgen, with targets ranging from Guggenheim's $340 drop to RBC's $350 hold.

🔬 Revenue growth relies on new drugs like IMDELLTRA while older franchises such as Prolia face decline.

⚠️ Growth faces headwinds from biosimilar competition and potential regulatory overhangs regarding Tepezza and TAVNEOS.

💊 Despite a dividend hike to $2.52, the stock trades at a 23x P/E with limited near-term upside.

🎯 Investors should monitor MariTide Phase 3 data as the key catalyst needed to justify higher valuations.

📉 Guggenheim reduced its price target on Amgen to $340 from $351 while maintaining a Neutral rating following the Q1 2026 earnings release.

📊 Amgen reported non-GAAP EPS of $5.15, beating the $4.77 consensus estimate, with revenue rising 6% year-over-year to $8.62 billion.

📈 Stock performance shows a split response as Amgen beat earnings but shares slipped 7% over the past month to trade at $324.

💰 Wall Street analysts are divided on the stock, with Morgan Stanley raising its target to $326 while RBC stands at $350 and JPMorgan at $340.

🔬 Amgen's portfolio is facing a bifurcation as newer drugs like IMDELLTRA grow significantly while older franchises Prolia and Enbrel decline.

💊 Repatha, Prolia, Otezla, Tepezza, and Enbrel remain key revenue drivers alongside the obesity candidate MariTide in late-stage development.

⚠️ The growth narrative is challenged by accelerating biosimilar competition, Medicare Part D pressures, and delays for MariTide against larger incumbents like Eli Lilly.

🏛️ Amgen's regulatory outlook includes a disappointed Tepezza post-Horizon and an FDA proposal to withdraw TAVNEOS adding potential overhang.

💵 The dividend was raised 6% to $2.52 per share, providing a steady income anchor for long-term holders amidst valuation concerns.

📉 Amgen trades at a P/E ratio of 23x with a consensus analyst target of $353.43, suggesting the current price reflects most near-term upside.

🛡️ Bulls view the stock as defensive with diversified cash flows, though the bull case hinges on MariTide success and Repatha momentum.

⏳ Investors should monitor Phase 3 data for MariTide, biosimilar pacing for Prolia, and generic timing for Repatha for future catalysts.

🎯 The Guggenheim cut is viewed as a model recalibration rather than a thesis shift, signaling limited upside at current levels.

🔍 Long-term holders may see this downgrade as a prudent adjustment given the biotech giant's slowing growth profile and franchise erosion.

⚖️ Moderate position sizing is recommended for income investors who recognize Amgen needs a clear catalyst to break meaning higher from current levels.

Bullish Signals
  • Amgen beat Q1 revenue and EPS expectations.
  • Revenue grew 6% YoY to $8.62 billion.
  • Management maintained full-year revenue guidance.
  • Dividend increased 6% to $2.52 per share.
  • High-growth segments surged with IMDELLTRA up 219%.
  • Bullish peers like RBC target stock at $350.
  • Market cap nears $178 billion.
  • Forward P/E of 15x shows reasonable valuation.
Risk Factors
  • Guggenheim cut Amgen price target from $351 to $340.
  • Stock declined 7% despite beating earnings expectations.
  • Prolia sales fell 34%; Enbrel dropped 37% due to biosimilars.
  • MariTide lags rivals by years in high-growth GLP-1 segment.
  • FDA withdrawal for TAVNEOS adds regulatory overhang.
Bullish Signals
  • Amgen beat first-quarter expectations on both revenue and earnings, delivering non-GAAP EPS of $5.15 versus the $4.77 consensus estimate.
  • Q1 revenue reached $8.62 billion, representing a 6% year-over-year increase that supports the company's growth profile despite competitive pressures.
  • Management maintained full-year guidance for revenue between $37.1 billion to $38.5 billion, signaling confidence in future performance.
  • Amgen raised its quarterly dividend by 6% to $2.52 per share, reinforcing its status as a defensive income play with a history of consistent payout increases.
  • High-growth portfolio segments demonstrated robust momentum, with IMDELLTRA growing 219%, UPLIZNA increasing 188%, and Repatha up 34%.
  • Despite analyst divergence on targets, significant peers like RBC maintain a $350 price target while Morgan Stanley raised its target to $326, indicating a bullish view exists among Wall Street institutions.
  • Amgen remains one of the largest U.S. biotechs by market capitalization near $178 billion, providing stability and scale for shareholders.
  • The forward P/E ratio of 15x suggests the stock is reasonably valued relative to future earnings, with a consensus analyst target price of $353.43 offering potential upside from recent levels.
Risk Factors
  • Guggenheim cut its price target on Amgen from $351 to $340 while maintaining a Neutral rating, signaling concerns that current valuation already reflects most of the upside potential.
  • Amgen stock has declined 7% over the past month despite beating earnings expectations, reflecting broader market caution on its growth profile.
  • Key franchises face significant erosion: Prolia sales fell 34% and Enbrel dropped 37% due to biosimilar competition and Medicare Part D pressure.
  • The obesity candidate MariTide lags behind major incumbents Eli Lilly and Novo Nordisk by years in development, creating a competitive disadvantage in the high-growth GLP-1 segment.
  • Revenue growth from core assets like Repatha (up 34%) is being offset by declining demand in others, leading to a bifurcated portfolio that may struggle to maintain total revenue momentum.
  • FDA regulatory overhang looms with proposed withdrawal approval for TAVNEOS and disappointed demand following the Horizons acquisition.
  • Tepezza demand has disappointed post-Horizon, adding uncertainty to one of the company's higher-priced specialty medicines.
  • Amgen's stock trades below the consensus analyst target of $353.43 (compared to Guggenheim's lowered $340), suggesting limited immediate upside catalysts according to cautious analysts.
Bullish +57

Amgen Earnings Call Highlights Growth Engines, Tax Risk

Amgen upgraded 2026 guidance to $37.1B–$38.5B revenue despite market headwinds.

High-growth franchises now drive 70% of sales, offsetting legacy brand declines.

AI initiatives cut antibody development timelines in half and boost efficiency.

📊 Amgen reported Q1 earnings with a cautiously upbeat tone, citing solid commercial momentum and upgraded guidance despite market headwinds.

💰 Total product sales grew modestly by 4% year-over-year, driven primarily by breadth across sixteen products with double-digit growth rather than reliance on a single blockbuster.

🚀 Six key high-growth franchises now account for roughly 70% of Amgen's product sales, providing a structural buffer against declining legacy assets.

💉 Repatha led revenue with $876 million in Q1 sales (up 34%), bolstered by new clinical data showing reduced cardiovascular events and growing physician confidence.

🦴 Evenity achieved strong 27% year-over-year growth to reach $562 million, effectively offsetting steep declines in older osteoporosis brands with a dominant U.S. market share.

🔬 The rare disease portfolio accelerated growth by 25% to $1.2 billion, highlighted by near-tripling sales of Eplisna and significant gains from TEPEZZA in oncology.

💊 Oncology and biosimilars segments delivered double-digit gains, with innovative oncology rising 25% to $1.8 billion and biosimilars growing 14% to $835 million.

📈 Amgen upgraded its 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS to $21.70–$23.10, supported by robust free cash flow of $1.5 billion in the quarter.

⚙️ Non-GAAP operating margins stood at 45%, reflecting disciplined cost control while management increased R&D spending by 16% and capital expenditures to $700 million for Q1.

🤖 Artificial intelligence initiatives are delivering operational efficiencies, including halving antibody lead-optimization timelines and drastically reducing production line clearance times.

⚠️ Legacy osteoporosis products face significant challenges with combined Prolia and XGEVA sales down 32%, and management warns of accelerated erosion through 2026 due to biosimilar competition.

💸 Cost of sales rose to 19.5% of product sales, driven by higher royalty obligations and an evolving mix that Amgen expects to remain a near-term headwind for margins.

🏛️ Regulatory setbacks include a proposed FDA withdrawal of approval for Tabneos and paused clinical trials for blinatumomab due to inflammatory events under review.

💸 Amgen faces undisclosed tax risks after receiving a draft IRS Notice challenging profit allocations for the years 2016–2018, adding to its list of financial pressures.

🧬 Pipeline development remains active with Meritide advancing through Phase III trials and Olpasiran showing over 95% reductions in Lp(a) levels in recent studies.

Bullish Signals
  • Overall sales grew 4% driven by high-growth franchises.
  • Six drivers delivered 70% of sales with 24% YoY growth.
  • 16 products achieved double-digit growth and 17 exceeded $1B annually.
  • Repatha sales surged 34% to $876 million in Q1.
  • Evenity grew 27% to $562 million holding 65% U.S. bone market.
  • Rare disease portfolio expanded 25% to $1.2 billion total.
  • Innovative oncology revenue rose 25% reaching $1.8 billion.
  • Biosimilar sales climbed 14% totaling $835 million including PABLUE.
  • 2026 guidance upgraded with EPS target of $21.70–$23.10.
  • Non-GAAP margin stayed robust at 45%.
  • Free cash flow generated was $1.5 billion in the quarter.
Risk Factors
  • Legacy osteoporosis sales dropped 32% to $1.1 billion amid lost exclusivity.
  • Biosimilar competition threatens accelerated revenue decline through 2026.
  • FDA proposed withdrawal of Tabneos approval causing regulatory friction.
  • Blincyto subcutaneous and SLE trials paused due to inflammatory events.
  • AMG 193 development discontinued despite pipeline investment risks.
  • Draft IRS Notice challenges profit allocations for tax years 2016–2018.
  • Non-GAAP cost of sales rose to 19.5% with no near-term relief.
Bullish Signals
  • Amgen reported modest overall sales growth of 4%, driven by high-growth franchises and offsetting pressure from legacy products.
  • Six key growth drivers generated roughly 70% of product sales in Q1 and grew 24% year over year, signaling a structural advantage in the portfolio mix.
  • Sixteen products posted double-digit growth, while 17 are now annualizing above $1 billion in sales, providing a wide base of scale to weather competitive pressures.
  • Repatha led growth with first-quarter sales of $876 million, up 34% year over year, supported by new data showing a 31% reduction in major cardiovascular events.
  • Evenity delivered impressive 27% year-over-year sales growth to $562 million, now holding about 65% of the bone-builder market in the U.S.
  • The rare disease portfolio grew 25% to $1.2 billion, with Eplisna sales nearly tripling to $262 million and TEPEZZA US sales rising 29% to $490 million.
  • Innovative oncology growth reached 25% to $1.8 billion, including significant contributions from Imdeltra ($258 million) and Blincyto (up 12% to $415 million).
  • Biosimilars remained a strong growth pillar with sales up 14% to $835 million, including $280 million from PABLUE in the quarter.
  • Management upgraded 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS guidance to $21.70–$23.10, reflecting confidence in future prospects.
  • Non-GAAP operating margin remained robust at 45%, while the company generated $1.5 billion of free cash flow in the quarter.
  • R&D spending climbed 16% year over year with capital expenditures reaching $700 million in Q1 and approximately $2.6 billion planned for the year to expand manufacturing capacity.
  • AI initiatives have significantly boosted operational efficiency, roughly halving antibody lead-optimization timelines and reducing production line clearance time from 30 minutes to roughly 2 minutes per batch.
Risk Factors
  • Loss of exclusivity is severely impacting legacy osteoporosis products, with combined Prolia and XGEVA sales declining 32% to $1.1 billion in the quarter.
  • Amgen warned of accelerated revenue erosion through 2026 as multiple biosimilars enter the market to compete with aging franchises.
  • The FDA proposed withdrawing approval for Tabneos, highlighting regulatory friction around specific portfolio assets.
  • Clinical trial enrollment for blinatumomab subcutaneous and SLE trials has been paused due to inflammatory events currently under FDA review.
  • Amgen discontinued development of AMG 193, demonstrating inherent risk in its pipeline where projects face discontinuation despite investments.
  • Amgen received a draft IRS Notice of Proposed Adjustment for tax years 2016–2018 challenging profit allocations, introducing significant potential tax liability and compliance costs.
  • Non-GAAP cost of sales rose to 19.5% of product sales driven by higher profit-share and royalty obligations, which management does not expect to ease near term.
Bullish +75

Amgen Earnings Call Highlights Growth Engines, Tax Risk

💰 Q1 product sales grew 4% while upgrading 2026 revenue guidance to $37.1–$38.5 billion.

📈 Top six growth drivers now account for 70% of total portfolio revenue.

⚠️ Risks include legacy osteoporosis erosion, clinical setbacks, and new tax audits.

📈 Amgen reported Q1 earnings with a cautiously upbeat tone, highlighting solid commercial momentum and upgraded revenue guidance.

💊 Growth engines now dominate the portfolio, with six key drivers generating roughly 70% of product sales and growing 24% year over year.

💰 Total product sales increased 4%, underpinned by breadth as 16 products posted double-digit growth and 17 annualized above $1 billion.

🩺 Repatha led revenue with Q1 sales of $876 million, up 34%, bolstered by new data showing a 31% reduction in major cardiovascular events for high-risk patients.

🦴 Evenity delivered strong growth with 27% year-over-year sales to $562 million, capturing about 65% of the U.S. bone builder market.

💉 Rare disease assets accelerated with a 25% portfolio growth to $1.2 billion, driven by Eplisna tripling in sales and TEPEZZA rising 29%.

🎯 Oncology and biosimilars delivered double-digit gains, with innovative oncology up 25% to $1.8 billion and biosimilars growing 14% to $835 million.

📊 Amgen upgraded its 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS guidance to $21.70–$23.10 based on strong free cash flow of $1.5 billion.

🔬 R&D spending climbed 16% year over year, supported by AI efficiencies that have halved antibody optimization timelines and streamlined regulatory documentation.

🏭 Capital expenditures reached $700 million in Q1, with roughly $2.6 billion planned for the year to expand manufacturing capacity for late-stage assets.

⚠️ Legacy osteoporosis products face accelerated erosion through 2026 as combined Prolia and XGEVA sales declined 32% to $1.1 billion due to biosimilar competition.

💸 Non-GAAP cost of sales rose to 19.5% of product sales, driven by higher royalty obligations and evolving product mix, creating near-term margin pressure.

⚖️ Regulatory and clinical setbacks included a proposed FDA withdrawal for Tabneos, trial pauses for blinatumomab, and the discontinuation of AMG 193 development.

🏛️ Amgen disclosed receipt of a draft IRS Notice of Proposed Adjustment challenging profit allocations for 2016–2018, introducing significant tax risk to future earnings.

Bullish Signals
  • Amgen sales grew 4% as high-growth franchises cushioned exclusivity losses.
  • Six drivers made up 70% of Q1 sales and grew 24% year over year.
  • Repatha sales rose 34% to $876 million with new cardiovascular data.
  • Evenity achieved 27% growth to $562 million in a dominant U.S. market.
  • Rare disease portfolio grew 25% to $1.2 billion driven by TEPEZZA and Eplisna.
  • Oncology sales increased 25% to $1.8 billion while biosimilars grew 14%.
  • Management raised 2026 revenue guidance to $37.1–$38.5 billion and EPS to $21.70–$23.10.
  • R&D spending climbed 16% as AI initiatives accelerated drug development timelines.
Risk Factors
  • Legacy drugs Prolia and XGEVA fell 32% to $1.1B in Q1.
  • FDA paused trials and dropped AMG 193 due to safety issues.
  • IRS challenge on 2016–2018 profits could severely impact earnings.
  • Non-GAAP cost of sales rose to 19.5% with no relief expected.
  • Capital expenditures projected at $2.6B strain operations significantly.
Bullish Signals
  • Amgen reported modest 4% overall sales growth driven by high-growth franchises, effectively cushioning the blow from drugs facing loss of exclusivity.
  • Six key growth drivers generated roughly 70% of Amgen's product sales in the first quarter and grew 24% year over year, demonstrating a structural advantage as older products decline.
  • Repatha stood out with first-quarter sales of $876 million, up 34% year over year, bolstered by new data showing a 31% reduction in major cardiovascular events in high-risk diabetes patients.
  • Evenity delivered 27% year-over-year sales growth to $562 million, including 35% growth in the U.S. where it now holds about 65% of the bone-builder market.
  • Amgen's rare disease portfolio grew 25% to $1.2 billion, with TEPEZZA's U.S. sales rising 29% to $490 million and Eplisna sales nearly tripling to $262 million.
  • The innovative oncology portfolio posted 25% growth to $1.8 billion, while biosimilars remained a growth pillar with sales up 14% to $835 million.
  • Management raised 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS guidance to $21.70–$23.10, reflecting confidence in the upgraded outlook.
  • Non-GAAP R&D spending climbed 16% year over year with AI initiatives that have roughly halved antibody lead-optimization timelines and tripled clinical site enrollment rates.
  • Capital expenditures reached $700 million in the quarter, with roughly $2.6 billion planned for the year to expand manufacturing capacity, including preparations for a potential Meritide launch.
Risk Factors
  • Total sales growth was modest at only 4%, while legacy products like Prolia and XGEVA suffered a 32% decline to $1.1 billion in Q1 due to biosimilar competition, signaling significant revenue erosion risks.
  • The FDA has proposed withdrawing approval for Tabneos and paused enrollment for blinatumomab and SLE trials due to inflammatory events, while development of AMG 193 was discontinued entirely, representing direct pipeline attrition.
  • Amgen faces a substantial tax risk as it received a draft IRS Notice of Proposed Adjustment for 2016–2018 challenging profit allocations, which could materially impact future earnings if finalized.
  • Non-GAAP cost of sales rose to 19.5% of product sales due to increased royalty obligations and product mix shifts, with management warning these margin pressures are unlikely to ease in the near term.
  • Capital expenditures for the year are projected at approximately $2.6 billion to expand manufacturing capacity and prepare for potential Meritide launches, placing significant financial strain on operations.
  • Rising costs and unresolved tax disputes continue to act as headwinds despite AI-enabled R&D gains and solid cash generation, limiting immediate upside to profitability metrics.
  • Accelerated sales erosion of older osteoporosis brands is expected to continue through 2026 as multiple biosimilars enter the market, creating pressure on overall portfolio growth.